Seed Health, a company working in microbiome science, has unveiled promising clinical data on their flagship product, VS-01 Vaginal Synbiotic. The findings will be presented at the 2024 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG). This study is the first to demonstrate that a multi-strain vaginal synbiotic can successfully establish a protective and optimal vaginal microbiome, dominated…
Researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the University of California Davis have developed a human Cervix-on-a-Chip. This model accurately mimics the complex cervical tissue and addresses the limitations of current animal and in vitro models, enhancing the study of bacterial vaginosis (BV) and fostering the development of more effective treatments. Bacterial Vaginosis affects over 25%…
Vaginal health takes center stage as Seed Health, a microbiome science company, unveils its latest innovation: VS-01 Vaginal Synbiotic. With a focus on redefining vaginal care, VS-01 represents a new vaginal synbiotic clinically validated to establish and sustain an optimal vaginal microbiome. Developed in collaboration with renowned vaginal microbiome scientist Dr. Jacques Ravel, VS-01 aims to address the critical role of the…
Today, Kindra, the sex-positive vaginal health brand, announced the launch of the first-ever comprehensive vaginal health product system – the Daily V System. The 4-part daily regimen of Kindra products includes: Daily Vaginal Lotion, V Relief Serum, Soothe Bath Soak and the Core Supplement meant to support vulvar and vaginal skin for optimal vaginal health and sexual wellness. This hormone-free system is designed to provide targeted relief and support for…
Organon, a global healthcare company focusing on women’s health, announced US-wide availability of XACIATO (clindamycin phosphate) vaginal gel 2% by prescription for the treatment of bacterial vaginosis (BV) in females aged 12 and older. BV, a condition resulting from an overgrowth of certain bacteria, disrupts the natural vaginal microbiome, leading to symptoms like odor and discharge. It affects approximately 21 million women…
Evvy, a startup dedicated to women’s health through data-driven precision care, has successfully raised $14M in a Series A funding round. The investment was led by Left Lane Capital, with participation from General Catalyst, Labcorp Venture Fund, RH Capital, Ingeborg Investments, G9 Ventures, Virtue, and Amboy Street Ventures. Founded in 2021, Evvy has been dedicated to reshaping women’s healthcare by leveraging data…
Biotech company Concerto Biosciences has announced a new strategic initiative to combat recurrent vaginal yeast infections. The company is dedicated to developing a novel microbial product, Ensemble No.3 (ENS-003), specifically targeting vulvovaginal candidiasis (VVC). This prevalent condition affects approximately 75% of women at some point in their lives and poses significant challenges due to limited protection provided by existing antifungal treatments. “All…
You’ve found some of our exclusive Inner Circle Content. This article is only available for our Inner Circle Members. To read on: Sign in to your Inner Circle account to access this content. If you aren’t a member yet and would like to find out more about our Inner Circle program or sign up, click here.
